Woman doctor dies by suicide in Rohini

New Delhi: In an unfortunate incident, a 26-year-old female doctor allegedly died by suicide at her house in Delhi’s Rohini on Sunday, police said. No suicide note was recovered from the scene.

A female doctor was found hanging in her room in Delhi’s Rohini on Sunday, police said.

The reason behind the suicide is yet to be ascertained, according to police, news agency PTI reported.

According to a media report in the HT, Deputy Commissioner of police (Rohini) Amit Goel said, “We received a call at around 3.15 pm from the family after they could not contact the woman. When our team of officers went to her house in Rohini Sector 8 and opened and entered it, they found her dead.”

Also Read:Woman doctor found dead under mysterious circumstances

A senior police officer said that she was married and was living separately in Rohini’s Sector 8.

According to the police, the woman and her husband had been living separately for a while, and she was staying alone in her house in Rohini Sector 8.

The body has been taken into custody, the officer said, adding that an investigation is launched.

While no foul play is suspected in the incident, police officers with knowledge of the matter believe that marital discord and domestic issues might have led her to take the step.

Also Read:Battling depression, 65-year-old doctor jumps to death from 42nd floor

Powered by WPeMatico

MCC Withdraws 2 Seats from NEET PG Special Vacancy Round, check out details

New Delhi- Through a notice, the Medical Counselling Committee (MCC) has informed about the withdrawal of some seats from the National Eligibility and Entrance Test-Postgraduate (NEET PG) special stray vacancy round counselling for the academic year 2024-25.

According to the notice, the MCC of DGHS received emails from two institutes Rana Beni Madhav Singh Hospital and Nalanda Medical College, Patna for the withdrawal of 2 seats each from the seat matrix of NEET PG Special Vacancy Round Counseling 2024-25. 2 seats have been removed from the ST category for General Medicine and ENT Specialty Courses. With this, these 2 seats will be removed for withdrawal from the seat matrix before the allotment process of Special Stray Vacancy of PG Counseling 2024.

Prior to this, MCC released the NEET PG Special Vacancy Round Counseling Clear Vacancy for the academic year 2024-25. As per the vacancies, a total of 733 seats are vacant for the NEET PG Special Vacancy Round Counselling 2024-25 across Medical Colleges in India.

Meanwhile, the registration and choice-filling process of the NEET PG Special Vacancy Round Counselling is ongoing and will end today i.e. 10th March 2025. Following this, the processing of seat allotment will start today, results will be published on 12th March 2025 and candidates can report to the allotted colleges from 13th March 2025.

SCHEDULE

S.NO

REGISTRATION AND CHOICE FILLING

PROCESSING OF SEAT ALLOTMENT

PUBLICATION OF RESULT

REPORTING AT ALLOTTED COLLEGE

1

6th March 2025 to 8th March 2025 (upto 11:00 A.M of 8th March.,2025)

Choice filling/locking will be available from 11:00 AM on 6th March 2025 till 08:00 AM on 10th March 2025 (as per Server timing)

10-11th March 2025

10-11th March 2025 12th March 2025

13th March 2025 to 20th March 2025 (upto 05:00 PM as per the Server timing)

DAYS

(5-Days)

(2-Day)

(1-Day)

(8-Days)

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/mcc-withdraws-2-seats-from-neet-pg-special-vacancy-round-counselling-2024-25-277851.pdf

Powered by WPeMatico

PMJAY Botched Angioplasty Case: Court denies bail to Khyati Hospital Director

Vadodara: The bail application of Rajshree Kothari, a director of Khyati Multispeciality Hospital, who was arrested in December 2024 for alleged involvement in the deaths of two Pradhan Mantri Jan Arogya Yojana (PMJAY) beneficiaries after botched angioplasty procedures, has been denied. The court rejected her application, citing that Kothari was aware of the potentially life-threatening risks of implanting stents in patients who did not require them. 

Stating that she intentionally misled the two deceased patients despite having full knowledge of medical protocols just to illegally obtain funds from the government, the Ahmedabad Rural court dismissed Kothari’s defense that she was merely a “non-executive director” and had no financial gain from the hospital’s operations.

Dismissing the bail plea, Principal District and Sessions Judge KM Sojitra highlighted that Kothari, despite her claims of being uninvolved in daily operations, was a director of the hospital and attended business meetings where strategies regarding organising free medical check-up camps were discussed. The court further stated that the investigating officer revealed that her husband held shares 6.31% in Khyati Multispeciality Hospital as well as another medical establishment, Ahmedabad Bariatric and Cosmetics Pvt. Ltd. 

Also read- PMJAY Deaths Case: Another Khyati Hospital Director arrested

Hinting the fact that a Director of a hospital couldn’t be unaware of any day to day activity of the hospital, the bench observed, “In pursuance to the conspiracy, the accused persons did not disclose the actual medical condition of the patients and misguided them to undergo angiography and angioplasty by placing stent in the body, though angiography/angioplasty was not required as per the medical protocol, with knowledge that if stents are placed in the person who do not require it then it would cause death of the person, and forged medical reports were prepared to create threat in mind of patient of medical emergency and avail money from government’s PMJAY scheme…Two people died on the same day when they were operated by Khyati Multispeciality Hospital and thereby, the accused have committed the offence as stated in the FIR…they performed the surgeries against medical protocol to illegally avail money from the government.”

Medical Dialogues had previously reported that Rajshree Kothari, one of the directors of Khyati Multispeciality Hospital, was held by a Crime Branch team in connection with the botched angioplasty surgeries when she and her husband Dr Pradip Kothari, were on their way to Bhilwara from Kota in Rajasthan.

It is to be noted that seven persons underwent angioplasty, a procedure that widens blocked or narrowed coronary arteries to improve blood flow to the heart, at Khyati Multispeciality Hospital on November 11, following which two of them died, prompting Vastrapur police to register three FIRs the next day.

The probe showed the hospital organised free check-up camps in villages to convince PMJAY cardholders to undergo angioplasty despite no medical necessity. They were shown in the “emergency” category to expedite government approval, after which the hospital claimed payments under the Central scheme.

Even though the Ahmedabad Court had previously denied anticipatory bail to Kothari, her counsel again applied for a regular bail a few days ago, which has been rejected again by the court. 

The court order was passed after Kothari’s counsel had sought regular bail on the ground that the police had completed the investigation and filed a chargesheet in the case. Advocate AK Shah, appearing for her, argued that she had no involvement in hospital management and “is innocent and has not committed any offence as stated in the FIR”, The Indian Express report.

Her defence argued that she is “the only lady director” and a “non-executive director” along with being a “house-wife in her life”. Therefore, she was unaware of any day-to-day activity of the hospital and was “not connected with any activity of angiography, angioplasty in any manner”.

In her bail application, Kothari stated that she had “not attended the annual general meeting, which was held on September 30, 2024 and cannot be made vicariously liable for the alleged offence.” She further submitted that she has “not received any remuneration or financial benefit” from the hospital nor was she part of any decision-making or management activity.

Opposing the bail application, Special Public Prosecutor Vijay Barot stated that the accused was part of a “conspiracy to illegally gain money from the Pradhan Mantri Jan Arogya Yojana scheme and as part of the conspiracy, the accused persons, who are directors, doctors and management persons with the intention to illegally gain money used to organise free medical camps and under the fear of health issues, patients were made to undergo angiography and angioplasty, though it was not required”.

The prosecution submitted that Kothari’s husband and other co-accused in the Khyati case are partners in Ahmedabad Bariatric and Cosmetics Pvt. Ltd. and her husband also holds 3.61% share in Khyati Multispeciality Hospital.

The order also highlighted the prosecution’s argument that after her husband’s retirement, Rajshree Kothari became a partner and was aware that the hospital was violating legal medical protocols by appointing BHMS and BAMS doctors for post-treatment observations instead of the legally required MBBS medical officer.

Also read- Ayushman Card Scam: Khyati Hospital Chairman sent to 6 days police remand

Powered by WPeMatico

How many PG medical seats available this year? Check out NMC’s updated seat matrix

New Delhi: The National Medical Commission (NMC) released the updated seat matrix for PG medical courses offered in medical colleges nationwide this year.

As per the seat matrix, around 49316 seats are available in MD, MS, and Diploma specialities. Out of the total seats, the maximum number of seats are available in the MD general medicine with 5349 seats followed by MS General Surgery 4905 and MD Anesthesiology with 4786 seats.

For Diploma specialities, the maximum seats are available in the speciality of anaesthesia with 104 seats as per the NMC notice; followed by Diploma In obstetrics & Gynaecology with 81 seats and ophthalmology with 73 seats. 

Below are the MD, MS seats details:

Speciality Total Seats
MD General
Medicine
5349
MS General
surgery
4905
MD
Anaesthesiology
4786
MS Obstetrics
& Gynaecology
4049
MD Paediatrics 3402
MS
Orthopaedics
2934
MD Pathology 2870
MD Radio
Diagnosis/Radiology
2663
MD/MS –
Ophthalmology
2008
MD Social
& PreventiveMedicine /Community Medicine
1787
MS
Otorhinolaryngology (ENT)
1614
MD Microbiology 1560
MD
Dermatology, Veneronology & Leprosy
1418
MD
Pharmacology
1314
MD Psychiatry 1269
MD/MS –
Anatomy
1223
MD Physiology 1187
MD
Bio-Chermistry
1098
MD
Tubercurosis & Respiratory Diseases/ Pulmonary Medicine
885
MD Forensic
Medicine /Forensic Medicine & Toxicology
732
MD Emergency
Medicine
470
MD
Radiotherapy/ Radiation Oncology
424
MD Respiratory
Medicine
221
MD Immuno
Haematology & Blood Transfusion
164
MD physical
Medicine & Rehabilitation
87
MD Geriatric 56
MD Hospital
Administration
42
MD Nuclear
Medicine
26
MD Palliative
Medicine
25
MD Sports
Medicine
21
MD Family
MEDICINE
20
MD- Aviation
Medicine/Aerospace Medicine
17
MD TRANSFUSION
MEDICINE
12
MD Tropical
Medicine
11
MS-TRAUMATOLOGY
& SURGERY
8
MD Lab
Medicine
5
MD Radiation
Oncology
5
MD Bio
Physics
1
Total Seats 48668

Below are the Diploma seats details:

speciality seats
Diploma in
Anaesthesia
104
Diploma In
obstetrics & Gynaecology
81
Diploma in
Ophthalmology
73
Diploma in
Chad Health
71
Diploma In
Radio Diagnosis
39
Diploma in
Orthopaedics
37
Diploma In
Oto-Rhino-laryngology
37
Diploma in
Dermatology venerealogy and Leprosy
32
Diploma In
Psychological Medicine
30
Diploma in
Clinical Pathology
24
Diploma in
Health Education
20
Diploma in
Tuberclosis & Chest Diseases
18
Diploma in
Public Health
14
Postgraduate
Diploma in Genetic Counselling
10
Diploma in
Community Medicine
7
Diploma in
Health Administration
6
Diploma in
Hospital Adminsiration
6
Diploma In
Radiation Medicine
6
Diploma In
Sports Medicine
6
Diploma in
Forensic Medicine
5
Diploma in
RadioTherapy
5
Diploma in
Diabetology
4
Diploma in
Microbiology
4
Diploma (
Marine Medicine )
2
diploma in
immuno haematology and blood transfusion
2
Diploma In
Physical Medicine & Raehabitation
2
Diploma in
public Health
2
Diploma in
Industrial Health
1
Grand Total 648

To view the NMC notice, click on the link below:

Powered by WPeMatico

Finerenone Benefits in HF With Mildly Reduced or Preserved Ejection Fraction Regardless of Baseline Risk: JAMA

UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in estimating heart failure risk and its potential role in guiding finerenone therapy.

The study, published in JAMA Cardiology, demonstrated that patients with heart failure with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) benefit from finerenone, regardless of baseline risk. The PREDICT-HFpEF models also performed well in calibration and discrimination, confirming their reliability.

For this purpose, the researchers conducted the FINEARTS-HF trial across 653 sites in 37 countries, enrolling adults aged 40 years and older with symptomatic heart failure and a left ventricular ejection fraction of 40% or greater. Participants were randomized between September 2020 and January 2023 to receive finerenone (titrated to 20 mg or 40 mg) or a placebo.

The study assessed the three PREDICT-HFpEF risk scores for cardiovascular death or heart failure hospitalization, cardiovascular death alone, and all-cause mortality. Predicted risk was compared with observed outcomes, and model performance was evaluated using the Harrell C statistic. The rates of predicted outcomes, including the composite of cardiovascular death and worsening heart failure events, were analyzed across risk quintiles, along with the effect of finerenone in different risk categories.

The study led to the following findings:

  • The FINEARTS-HF trial included 6001 patients with a mean age of 72 years, with 54.5% being male.
  • The PREDICT-HFpEF model performed well in predicting cardiovascular outcomes, with C statistics of 0.71 for cardiovascular death or heart failure hospitalization, 0.68 for cardiovascular death, and 0.69 for all-cause death at two years.
  • Patients in the highest risk quintile had an 8- to 10-fold greater risk of composite outcomes than those in the lowest quintile.
  • Finerenone consistently reduced risk across all patient groups, with no significant difference in effect based on baseline risk.

The researchers demonstrated that the PREDICT-HFpEF model effectively assessed risk in patients with HFmrEF or HFpEF, showing strong calibration and discrimination. Despite the wide range of risk levels among participants, the baseline risk did not alter the therapeutic benefits of finerenone. Those at the highest risk experienced the most significant absolute benefit when the drug was added to their treatment.

“These findings highlight the consistent efficacy of finerenone across risk groups and support the integration of predictive models like PREDICT-HFpEF to enhance individualized heart failure management,” the researchers concluded.

They noted limitations, including trial-specific patient selection, and limiting generalizability. One missing variable may have affected accuracy, and socioeconomic factors were not analyzed. Additionally, alternative HFpEF risk scores may provide different predictive insights.

Reference:

McDowell K, Docherty KF, Campbell RT, et al. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. Published online March 05, 2025. doi:10.1001/jamacardio.2025.0025

Powered by WPeMatico

METS-VF Score: A Promising Tool for Early Diabetes Detection, Indian Study Finds

India: A recent study based on data from the National Health and Nutrition Examination Survey (NHANES) 2011-2018 highlights the effectiveness of the Metabolic Score for Visceral Fat (METS-VF) in predicting diabetes mellitus. The study, published in PLoS ONE, found that METS-VF is a strong predictor of left ventricular hypertrophy (LVH) in individuals with type 2 diabetes (T2DM), outperforming conventional obesity markers.

The prevalence of LVH increased progressively across METS-VF quartiles, ranging from 7.9% to 31%. Higher METS-VF levels were associated with a nearly tenfold greater risk of developing LVH (OR: 9.79). These findings suggest that METS-VF could be a valuable tool for early cardiac risk assessment in T2DM patients.

The researchers note that visceral fat, which accumulates around internal organs, is a well-established risk factor for metabolic disorders, including diabetes. With obesity affecting 42.4% of the U.S. population, the prevalence of diabetes mellitus (DM) continues to rise, highlighting the need for effective assessment tools. Traditional methods for measuring visceral adipose tissue (VAT), such as imaging techniques, are often costly and impractical for routine use. The METS-VF offers a simple yet effective alternative by integrating metabolic parameters to estimate VAT levels.

Against the above background, Amandeep Singh, Affiliation Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India, and colleagues investigated the association between METS-VF and the risk of developing DM, emphasizing its potential as a practical tool for early risk assessment.

For this purpose, the researchers analyzed data from the NHANES dataset, spanning the 2011–2018 cycles. They employed multivariate logistic regression and Receiver Operating Characteristic (ROC) analysis to evaluate the association between METS-VF and DM. Furthermore, they compared various VAT measurement indices with METS-VF to assess its predictive ability for DM.

The study led to the following findings:

  • Among 3,445 participants, METS-VF showed a strong positive association with diabetes (OR: 6.8) with an AUC of 0.791.
  • The association between METS-VF and diabetes increased across quartiles, with METS-VF >6.5 linked to significantly higher risk (OR: 53.8).
  • METS-VF demonstrated superior ability in identifying diabetes compared to other visceral adipose tissue (VAT) indices, including lipid accumulation product (LAP), visceral adiposity index (VAI), waist circumference, and waist-to-height ratio (WHtR).
  • Premenopausal females with a BMI >25 and METS-VF >6.5 had an elevated risk of developing diabetes.

The researchers found a strong association between METS-VF and the prevalence of diabetes, highlighting its effectiveness as a tool for visceral adipose tissue measurement. Compared to other surrogate markers, METS-VF demonstrated superior predictive ability, making it a valuable option for routine clinical assessments.

“Given its reliability across different demographic and lifestyle factors, integrating METS-VF into daily practice and large-scale epidemiological studies could aid in the early identification of individuals at risk of diabetes, enabling timely intervention and improved disease management,” they concluded.

Reference:

Tripathi, H., Singh, A., Prakash, B., Dubey, D. K., Sethi, P., Jadon, R. S., Ranjan, P., & Vikram, N. K. (2025). The Metabolic Score for Visceral Fat (METS-VF) as a predictor of diabetes mellitus: Evidence from the 2011–2018 NHANES study. PLOS ONE, 20(2), e0317913. https://doi.org/10.1371/journal.pone.0317913

Powered by WPeMatico

Improvement of Sleep Health may halt progression of gestational diabetes to type 2 diabetes: JAMA

Research indicates that improving sleep health plays a crucial role in preventing the progression from gestational diabetes (GD) to type 2 diabetes (T2D) in women. Researchers have found in a new study that by Improving Sleep health, the progression of gestational diabetes to type 2 diabetes may be prevented.

Women with a history of gestational diabetes (GD) are at high risk for developing type 2 diabetes (T2D). Sleep is a crucial lifestyle factor associated with cardiometabolic health, yet studies on its role in the progression from gestational diabetes to T2D are sparse.

A study was done to investigate the associations of sleep duration and quality with T2D risk and levels of glucose metabolism biomarkers in women with a history of GD. Design, Setting, and Participants This cohort study used data from the Nurses’ Health Study II, an ongoing longitudinal cohort that began in 1989 and initially included 116 429 female nurses with health status and lifestyle factors updated every 2 to 4 years.

A subset of participants with a history of gestational diabetes was followed up through June 2021. Sleep characteristics were assessed in the 2001 questionnaire (administered from June 2001 to June 2003), which served as the baseline for follow-up. Data were analyzed from November 2023 to August 2024. Physician-diagnosed incident T2D was ascertained biennially via questionnaires. Cox proportional hazards regression models were used to estimate the hazard ratios (HRs) and 95% CIs. Biomarkers (glycated hemoglobin [HbA1c], C-peptide, and insulin) were compared across sleep characteristic categories using multivariable-adjusted least-squares means (LSMs) and 95% CIs. Results During a total of 42 155 person-years of follow-up among 2891 women with a history of gestational diabetes (mean [SD] age, 45.3 [4.4] years), 563 women (19.5%) developed type 2 diabetes.

Compared with women who reported rarely snoring, those with occasional or regular snoring had significantly higher T2D risk, with adjusted HRs of 1.54 (95% CI, 1.18-2.02) and 1.61 (95% CI, 1.21-2.13), respectively. Compared with women who slept 7 to 8 hours per day, shorter sleep duration (≤6 hours per day) was significantly associated with a higher risk of type 2 diabetes (HR, 1.32; 95% CI, 1.06-1.64). Women who slept 6 or fewer hours per day and snored regularly had the highest risk of developing type 2 diabetes.

Additionally, more frequent snoring was associated with higher HbA1c, C-peptide, and insulin levels in the full adjusted models. In this cohort study of women with a history of gestational diabetes, shorter sleep duration and both occasional and regular snoring were significantly associated with an increased risk of type 2 diabetes. These findings suggest that improving sleep health may be important to reduce type 2 diabetes incidence in this high-risk population.

Reference:

Yin X, Bao W, Ley SH, et al. Sleep Characteristics and Long-Term Risk of Type 2 Diabetes Among Women With Gestational Diabetes. JAMA Netw Open. 2025;8(3):e250142. doi:10.1001/jamanetworkopen.2025.0142

Powered by WPeMatico

Omalizumab treats multi-food allergy better than oral immunotherapy, unravels study

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens. OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it. Thirty-six percent of study participants who received an extended course of omalizumab could tolerate 2 grams or more of peanut protein, or about eight peanuts, and two other food allergens by the end of the treatment period, but only 19% of participants who received multi-food OIT could do so. Researchers attributed this difference primarily to the high rate of allergic reactions and other intolerable side effects among the participants who received OIT, leading a quarter of them to discontinue treatment. When the participants who discontinued therapy were excluded from the analysis, however, the same proportion of each group could tolerate at least 2 grams of all three food allergens.

The findings were published in an online supplement to The Journal of Allergy and Clinical Immunology and presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress in San Diego on Sunday, March 2, 2025.

“People with highly sensitive multi-food allergy previously had only one treatment option-oral immunotherapy-for reducing their allergic response to moderate amounts of those foods,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the study’s funder and regulatory sponsor. “This study shows that omalizumab is a good alternative because most people tolerate it very well. Oral immunotherapy remains an effective option if treatment-related adverse effects are not an issue.”

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions. This renders these cells much less sensitive to stimulation by any allergen.

The current study is the second stage of a landmark clinical trial that found a 16-week course of omalizumab increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction. This next stage of the trial was designed to directly compare omalizumab with OIT for the first time.

At 10 locations across the United States, the study team enrolled 177 children and adolescents ages 1 to 17 years and three adults ages 18 to 55 years, all with confirmed allergy to less than half a peanut and similarly small amounts of at least two other common foods among milk, egg, cashew, wheat, hazelnut or walnut. After completing the first stage of the trial, 117 individuals entered the second stage of the trial.

Upon beginning Stage 2, all participants received injections of omalizumab for eight weeks. Then the participants were randomly divided in half and placed into one of two groups. Group A received omalizumab injections and multi-allergen OIT for eight weeks, while group B received omalizumab injections and placebo OIT for eight weeks. Subsequently, group A received placebo injections and multi-allergen OIT for 44 weeks, while group B continued to receive omalizumab injections and placebo OIT for 44 weeks. Neither the participants nor the investigators knew who was in which treatment group.

Group A received omalizumab before and during their early months of OIT because data from prior studies suggested that pretreatment with the medication would significantly augment the safety of OIT, and continuing omalizumab during the early months of OIT would provide additional benefit.

During the study treatment period, 29 of 59 participants in group A discontinued therapy: 15 due to allergic reactions-some severe-or other intolerable symptoms of OIT, and 14 for other reasons, including aversion to the study foods or the burden of participating in the trial. No participants in group B had allergic reactions or other side effects from omalizumab that led them to discontinue therapy, but seven participants in group B left the study mainly due to the burden of participating in it. In all, 30 of the original 59 members of group A (51%) and 51 of the original 58 members of group B (88%) completed treatment.

After the study treatment period, the clinical trial team tested whether the participants who completed therapy could eat at least 2 grams of peanut protein and their two other study foods without an allergic reaction. Twenty-one of the original 58 participants in group B, or 36%, could tolerate at least 2 grams of all three foods, while only 11 of the original 59 participants in group A (the OIT-treated group), or 19%, could do so. When evaluating only the participants who completed therapy, however, the same proportion of each group could tolerate at least 2 grams of all three foods.

These results showed that omalizumab was more effective than OIT at treating multi-food allergy in people who originally had a very low tolerance to common food allergens. Investigators attributed this outcome mainly to the high rate of allergic reactions and other side effects leading to treatment discontinuation among the OIT-treated participants, despite receiving omalizumab before and during the early months of therapy.   

Reference:

RA Wood et al. Treatment of multi-food allergy with omalizumab compared to omalizumab-facilitated multi-allergen OIT. Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2024.12.1022 (2025).

Powered by WPeMatico

Depression positively correlated with gynecologic cancers, suggests study

An NHANES-based study found that high depression scores correlated with an increased risk of ovarian and endometrial cancers. Among 11,574 participants, those with gyneoclogical cancers had significantly higher PHQ-9 scores. Depression was associated with ovarian and endometrial cancer but not cervical cancer. These findings highlight the importance of mental health screening in cancer risk assessment.

Depression is one of the leading sources of disease burden globally and plays a significant role in the occurrence and development of many cancers, representing an important health risk. However, the relationship between depression and the risk of gynecologic cancers has not been fully assessed. This study aims to explore the association between depression and the risk of gynecologic cancers. They selected 11,574 participants from the NHANES 2009–2018 cycles, among which 274 had gynecologic cancer (GC), 137 had cervical cancer (CC), 48 had ovarian cancer (OC), and 89 had endometrial cancer (EC). Box plots were used to assess the differences in PHQ-9 depression scores between cancer and non-cancer groups. Logistic regression models and restricted cubic spline (RCS) models were employed to evaluate the relationship between PHQ-9 scores and gynecologic cancers. Subgroup analyses and interaction tests examined the consistency of the association across different characteristics. Results: There was a significant difference in PHQ-9 scores between the cancer group and the non-cancer group. In the multivariable logistic regression analysis, PHQ-9 scores were positively correlated with gynecologic cancers, ovarian cancer, and endometrial cancer, while no significant association was found with cervical cancer risk. Additionally, the RCS model also indicated no nonlinear association between PHQ-9 scores and cervical cancer risk. Additionally, subgroup analyses suggested that the relationship between PHQ-9 scores and cervical cancer and ovarian cancer was consistent across groups, whereas the association between PHQ-9 scores and gynecologic cancers and endometrial cancer showed heterogeneity about race and marital status. Depression is positively correlated with gynecologic cancers. Specifically, higher levels of depression are associated with an increased risk of ovarian cancer and endometrial cancer, while no significant association was found with cervical cancer risk. Future attention should be given to the impact of depression on the incidence of gynecologic cancers, particularly ovarian cancer and endometrial cancer.

Reference:

Wang, C., Xu, J., Li, X., & Jiang, L. (2025). Depression as a Risk Factor for Gynecological Cancers: Evidence from NHANES Data. International Journal of Women’s Health, 17, 615–625. https://doi.org/10.2147/IJWH.S504049

Keywords:

Wang, C., Xu, J., Li, X., & Jiang, L., Depression, Risk Factor, Gynecological, Cancers: Evidence, NHANES Data, Wang, C., Xu, J., Li, X, Wang, C., Xu, J., Li, X

Powered by WPeMatico

Customized Zirconia Membranes effective for Alveolar Ridge Augmentation: A systematic review

Researchers have found in a systematic review of case series and reports that customized zirconia membranes have proven effective in alveolar ridge augmentation. This supports successful dental implant placement with minimal complications, particularly low membrane exposure rates. However, no studies establish zirconia’s superiority over other materials or determine the optimal design and bone grafting strategy for these membranes.

Since the inception of intraosseous implants, the significance of alveolar bone volume has become crucial in formulating treatment plans for dental implants. Various barrier membranes have been extensively employed in alveolar ridge reconstruction, highlighting their efficacy. Recent advancements include the fabrication of customized barrier membranes using multiple materials, with titanium and zirconia being prominent choices. The objective of this study was to conduct a comprehensive review of all clinical studies, case reports, and case series that utilized customized zirconia membranes for alveolar ridge augmentation. An electronic literature search was performed to find relevant clinical studies, case reports, and case series published in English up to August 2024. The following keywords used in the search were customized zirconia membrane, alveolar ridge augmentation, Guided bone regeneration, zirconia sheet, ceramic sheet, and Personalized membrane. The quality assessment was conducted using the Joanna Briggs Institute (JBI) critical appraisal checklist specific to each type of study. Results: The electronic search initially yielded 539 articles. Following deduplication, 263 unique articles remained. Subsequent manual screening of titles and abstracts led to the exclusion of 250 articles, resulting in 13 remaining articles. After conducting a thorough full-text assessment of these 13 articles to verify adherence to the inclusion/exclusion criteria, 6 articles were further excluded, leaving a total of 7 articles included in this review. While all studies included in this review were case series or case reports, customized zirconia membranes have demonstrated effectiveness in the literature for alveolar ridge augmentation, facilitating the placement of dental implants in all cases with relatively low complication rates, particularly membrane exposure. There is currently no literature evidence supporting the superiority of zirconia over other materials used in customized fabrication, nor is there evidence of superior design or preferred bone grafting under these membranes.

Reference:

Albash, Z., Khalil, A., & Kashkash, W. (2024). Alveolar Ridge Augmentation using Customized Zirconia Membranes: A Systematic Review. The Open Dentistry Journal, 9 December 2024. https://doi.org/10.2174/0118742106356292241122070017

Keywords:

Customized membrane, Alveolar ridge augmentation, Guided bone regeneration, Zirconia sheet, Ceramic sheet, Personalized membrane, Zirconia, Systematic review, Albash, Z., Khalil, A., & Kashkash, W

Powered by WPeMatico